Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-11-27 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
Form of Proxy for the Second Extraordinary General Meeting of 2024 (Applicable to H Shareholders)
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Form of Proxy for the Second Extraordinary General Meeting (EGM) of 2024, sent to H shareholders to appoint proxies and vote on resolutions (board composition, capital reduction, amendments, etc.). This is clearly a proxy solicitation form and part of the materials requesting shareholder votes for a meeting. Under the classification definitions, it best fits “Proxy Solicitation & Information Statement” (PSI).
2024-11-27 English
NOTICE OF THE SECOND H SHARE CLASS MEETING OF 2024
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice of the second H Share Class Meeting, detailing the meeting date/time, special resolution (cancellation of repurchased A shares and capital reduction), proxy appointment instructions, and closure of register of members. It is distributed to shareholders to provide information on the upcoming vote and solicit their proxy forms. This matches the definition for Proxy Solicitation & Information Statement (PSI).
2024-11-27 English
NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2024
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice announcing the date, time, venue, agenda items, and proxy arrangements for the Second Extraordinary General Meeting of 2024. It solicits shareholder attendance and proxy voting on specified resolutions. This aligns with the definition of Proxy Solicitation & Information Statement (materials sent to shareholders to provide information and request votes for meetings).
2024-11-27 English
(1) PROPOSED CHANGE IN COMPOSITION OF THE BOARD&#x3b; (2) PROPOSED AMENDMENT TO THE INDEPENDENT NON-EXECUTIVE DIRECTORS WORKING POLICY&#x3b; (3) PROPOSED CANCELLATION OF REPURCHASED A SHARES AND REDUC
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular issued by Pharmaron Beijing Co., Ltd. in connection with an Extraordinary General Meeting and a class meeting, providing detailed background on proposed resolutions, amendments to articles, capital reduction, board composition changes, and including notices of meetings and proxy forms. It requests votes and furnishes information for shareholder decision-making, matching the definition of a Proxy Solicitation & Information Statement. It is not a full annual or interim report, earnings release, regulatory filing, or presentation. Therefore it is classified as PSI.
2024-11-27 English
ANNOUNCEMENT ON (I) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; (II) PROPOSED CHANGE IN COMPOSITION OF THE BOARD&#x3b; (III) PROPOSED AMENDMENT TO THE INDEPENDENT NON-EXECUTIVE DIRECTORS W
Board/Management Information Classification · 91% confidence The document is a corporate announcement by a Hong Kong‐listed company regarding the resignation of an independent non‐executive director, proposed changes in board composition, amendments to director working policies and articles of association, and related general meeting arrangements. The primary focus is on board and senior management changes. This matches the definition of Board/Management Information (MANG).
2024-11-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, warrants, convertibles, other agreements to issue shares, and repurchase of shares. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and shareholding movements for a specific month. It is not a financial report like an annual or interim report, nor is it a call transcript, audit report, or governance document. It is a regulatory filing reporting share capital and share movements as required by exchange rules. The document length is 8809 characters, which is substantive and contains detailed data, not just an announcement or certification. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital movements that does not fit more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) because it covers multiple types of share movements and confirmations in one regulatory return form.
2024-11-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.